Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Telephone/Fax Amendments Are "Highest Priority" For ANDA Reviewers

This article was originally published in The Tan Sheet

Executive Summary

Telephone and facsimile ANDA amendments will be designated as "highest priority" by FDA reviewers, the agency says in its recent guidance on "Major, Minor, Fax and Telephone Amendments to Original Abbreviated New Drug Applications."

You may also be interested in...

OGD Hopes To Reach 315 ANDA Approvals In 2000, Up 30% Over Slow 1999

FDA's Office of Generic Drugs estimates it could approve or tentatively approve 315 generic drug applications in calendar year 2000, a 30% increase from 1999.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts